BBI

Why Brickell Biotech Shares Are Trading Lower Today

BBI Stock Fell Over 20% Pre-Market: Why It Happened

Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million

Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock

Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q1 2021 Results - Earnings Call Transcript